Browse the evidence

Metabolic therapies like tirzepatide can reduce weight and improve OSA severity.

Incorporating metabolic therapies may enhance treatment strategies for patients with obesity and OSA.

GLP-1 receptor agonists achieve clinically significant weight loss of 15–22.5% total body weight.

GLP-1 RAs can be considered effective options for achieving significant weight loss in obesity management.

GLP-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists provide clinically meaningful weight loss of approximately 15%–21% at 68–72 weeks in major trials.

Practitioners can expect significant weight loss in patients using GLP-1 therapies over the specified duration.

Semaglutide reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% in adults with established cardiovascular disease.

GLP-1 therapies may also provide cardiovascular benefits, which is important for patient management.

Incretin-based therapies have transformed the management of obesity and type 2 diabetes, with GLP-1RAs achieving levels of weight loss that begin to narrow the gap with metabolic surgery in selected populations.

Practitioners should consider incretin-based therapies as effective options for weight management in patients with obesity and type 2 diabetes.

Participants using the program plus medication were more likely to achieve clinically significant weight loss, with odds ratios ranging from 1.46 to 2.57 for ≥5% weight loss across timepoints.

Integrating a behavioral support app with GLP-1 RA treatment can significantly enhance weight loss outcomes.

Progress logging was associated with greater weight loss over time.

Encouraging users to log their progress can lead to better weight loss results.

Medication type was the strongest determinant of weight loss over time, with tirzepatide producing greater early reductions.

Choosing the right GLP-1 RA can significantly impact weight loss success.

Retatrutide yields a 24.2% reduction in total body weight at 48 weeks with 63% of participants achieving a total body weight loss of ≥20%.

Retatrutide may be an effective option for significant weight loss in patients.

Strength training can improve the quality of life of older adults with sarcopenia.

Practitioners should consider implementing strength training programs for older adults with sarcopenia to enhance their quality of life.

Strength training is more effective in high-intensity and supervised interventions.

Focus on high-intensity and supervised strength training for better outcomes.

Tirzepatide treatment resulted in a mean weight loss of 9.94 ± 4.8 kg and a percentage weight loss of 9.7 ± 4.8 % after 4 months.

Tirzepatide can be an effective option for weight management in patients with obesity.

Significant reductions were observed in body weight, BMI, waist circumference, absolute fat mass, body fat percentage, and visceral fat index.

Tirzepatide effectively reduces various measures of body fat in patients with obesity.

Whey protein supplementation had a significant effect on bench press performance (MD 5.72; 95% CI:1.30, 10.15; p=0.02).

Practitioners may consider recommending whey protein to enhance upper body strength in young adults involved in resistance training.

Protein supplementation has no negative effects on kidney performance in healthy adults who perform resistance training.

Practitioners can consider protein supplementation safe for kidney health in healthy adults engaged in resistance training.

Ingestion of whey protein during recovery from exercise increases myofibrillar protein synthesis rates.

Practitioners should consider whey protein as an effective supplement for enhancing muscle recovery post-exercise.

Protein ingestion increased circulating plasma amino acid concentrations.

Protein supplementation can effectively elevate amino acid levels in the bloodstream post-exercise.

Whey protein supplementation significantly improved bench press performance by a mean difference of 8.87 (95% CI: 5.95-11.79) and squat performance by a mean difference of 9.60 (95% CI: 5.61-13.60).

Practitioners can recommend whey protein to enhance strength performance in young adults engaged in resistance training.

Protein supplementation increased peak plasma total essential amino acids (EAA).

Practitioners can expect protein supplementation to enhance amino acid availability in young adults.

Regular strength training is highly effective for the prevention and treatment of sarcopenia.

Practitioners should implement regular strength training programs for older adults to prevent sarcopenia.

High-intensity training with 2 sessions of 30-45 minutes each is an efficient method for older adults.

Older adults should engage in high-intensity training sessions to maximize efficiency.

Supplementing strength training with adequate protein (≈1.6 g/kg) and creatine (≈3 g/d) enhances effects.

Practitioners should recommend protein and creatine supplementation alongside strength training for older adults.

Resistance training combined with dietary protein supplementation has synergistic benefits for older adults with sarcopenia or physical frailty, with a potential ceiling effect at 1.5-1.7 g PRO/kg BW/day.

Practitioners should recommend a combination of resistance training and protein supplementation within the specified range for older adults.

Whey-based multi-ingredient supplements are superior to isocaloric and isonitrogenous placebo for enhancing skeletal muscle growth in both younger and older persons.

Whey-based multi-ingredient supplements should be prioritized for muscle growth in diverse age groups.